- Data analytics company Ixico signed contracts with two biopharmaceutical companies to provide its technology-enabled imaging services to support an early phase study in Huntington's Disease and a phase 3 study in another rare neurological disease.

As the selected imaging analysis partner for these studies, IXICO would sue its data analytics expertise to 'provide critical insights which will support the evaluation of drug safety and efficacy,' with study planning and site set-up activities 'due to start imminently, contributing revenues for 2019 and into future periods,' the company said.

The Huntington's Disease contract had a total value of approximately £2.0m, which would be delivered over a seven-year term.

The second contract was with a company undergoing a phase 3 study in another rare neurological disease.

This was initially a start-up agreement to enable IXICO to begin to deploy its services to the study which anticipated recruiting patients in June 2019. 'A contract for the full study is expected to be completed in the coming months,' the company added.

At 9:28am: [LON:IXI] IXICO plc share price was +1p at 27p

Story provided by